VICTOR analysis shows increased CV events with Vioxx

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2007年 / 1163卷 / 1期

关键词：

Placebo Recipient; Rofecoxib; Colorectal Cancer Surgery; Tumour Recurrence Rate; Voluntary Withdrawal;

D O I：

10.2165/00128415-200711630-00009

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：4 / 4

相关论文

共 50 条

[1] CV events persist for one year after stopping Vioxx
Reactions Weekly, 2008, 1225 (1) : 1 - 1
[2] Celecoxib: no increased risk of CV events
Reactions Weekly, 2002, 892 (1) : 4 - 4
[3] Trial shows effects of hypertension on dementia, CV events
不详
GERIATRICS, 2005, 60 (10) : 12 - 12
[4] Testosterone therapy: increased risk of CV events
Reactions Weekly, 2014, 1489 (1) : 2 - 2
[5] The VICTOR Trial (VIOXX® in colorectal cancer therapy, definition of optimalregime)
Pendlebury, S
Duchesne, F
Reed, KA
Smith, JL
Kerr, DJ
BRITISH JOURNAL OF CANCER, 2003, 88 : S68 - S68
[6] VIOXX and cardiovascular events: a class effect?
Berenbaum, F
JOINT BONE SPINE, 2005, 72 (01) : 1 - 3
[7] No increased risk of CV events with dutasteride vs finasteride
Reactions Weekly, 2016, 1630 (1) : 9 - 9
[8] JUPITER Study Shows Crestor® Significantly Lowers Major Cardiovascular (CV) Events
不详
PHYSICIAN AND SPORTSMEDICINE, 2008, 36 (01): : 7 - 7
[9] Amlodipine/nifedipine GITS: no increased risk of death or CV events
Reactions Weekly, 1998, 689 (1) : 5 - 5
[10] Study observes increased risk for CV events in men with migraines
不详
FORMULARY, 2007, 42 (01) : 60 - 60

← 1 2 3 4 5 →